Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacogenetic Considerations in the Treatment of Alzheimer’s Disease
Ramón Cacabelos, Clara Torrellas, Óscar Teijido, et al.
Pharmacogenomics (2016) Vol. 17, Iss. 9, pp. 1041-1074
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Ramón Cacabelos
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 3, pp. 551-551
Open Access | Times Cited: 499
ADME profiling, molecular docking, DFT, and MEP analysis reveal cissamaline, cissamanine, and cissamdine from Cissampelos capensis L.f. as potential anti-Alzheimer's agents
Maram B. Alhawarri, Mohammad G. Al‐Thiabat, Amit Dubey, et al.
RSC Advances (2024) Vol. 14, Iss. 14, pp. 9878-9891
Open Access | Times Cited: 21
The role of pharmacogenomics in adverse drug reactions
Ramón Cacabelos, Natalia Cacabelos, Juan C. Carril
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 5, pp. 407-442
Closed Access | Times Cited: 98
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Ramón Cacabelos, Olaia Martínez-Iglesias, Natalia Cacabelos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-28
Closed Access | Times Cited: 1
Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics
Ramón Cacabelos, Juan C. Carril, Natalia Cacabelos, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1249-1249
Open Access | Times Cited: 76
Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?
Ramón Cacabelos
Expert Opinion on Drug Discovery (2018) Vol. 13, Iss. 6, pp. 523-538
Closed Access | Times Cited: 62
Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
Ramón Cacabelos, Vinogran Naidoo, Lola Corzo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13302-13302
Open Access | Times Cited: 46
Pharmacogenetics of Anxiety and Depression in Alzheimer’s Disease
Ramón Cacabelos, Juan C. Carril, Lola Corzo, et al.
Pharmacogenomics (2023) Vol. 24, Iss. 1, pp. 27-57
Closed Access | Times Cited: 22
Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases
Óscar Teijido, Ramón Cacabelos
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 3199-3199
Open Access | Times Cited: 57
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Ramón Cacabelos
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3059-3059
Open Access | Times Cited: 48
Pharmacogenomics of Alzheimer’s and Parkinson’s diseases
Ramón Cacabelos
Neuroscience Letters (2018) Vol. 726, pp. 133807-133807
Closed Access | Times Cited: 43
Peptides as epigenetic modulators: therapeutic implications
Yorick Janssens, Evelien Wynendaele, Wim Vanden Berghe, et al.
Clinical Epigenetics (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 32
Review on application and development of pharmacogenomics of adverse drug reactions
Hongyun Bi, Jun Zhu, Yuanxuan Cai, et al.
Journal of Holistic Integrative Pharmacy (2025) Vol. 6, Iss. 1, pp. 105-116
Open Access
Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease
Ramón Cacabelos, Arun Meyyazhagan, Juan C. Carril, et al.
Journal of Personalized Medicine (2018) Vol. 8, Iss. 1, pp. 3-3
Open Access | Times Cited: 30
Simple analogues of natural product chelerythrine: Discovery of a novel anticholinesterase 2-phenylisoquinolin-2-ium scaffold with excellent potency against acetylcholinesterase
Bohang Zhou, Hui Li, Zhiming Cui, et al.
European Journal of Medicinal Chemistry (2020) Vol. 200, pp. 112415-112415
Closed Access | Times Cited: 26
Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
Fabricio Ferreira de Oliveira, Elizabeth Chen, Marı́lia de Arruda Cardoso Smith, et al.
Journal of Molecular Neuroscience (2020) Vol. 70, Iss. 10, pp. 1574-1588
Closed Access | Times Cited: 26
Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
Fabricio Ferreira de Oliveira, Paulo Henrique Ferreira Bertolucci, Elizabeth Chen, et al.
Journal of Alzheimer s Disease (2022) Vol. 87, Iss. 1, pp. 359-372
Closed Access | Times Cited: 15
The Epigenetic Machinery in the Life Cycle and Pharmacoepigenetics
Ramón Cacabelos, Iván Tellado, Pablo Cacabelos
Elsevier eBooks (2019), pp. 1-100
Closed Access | Times Cited: 23
Personalized Management and Treatment of Alzheimer’s Disease
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, et al.
Life (2022) Vol. 12, Iss. 3, pp. 460-460
Open Access | Times Cited: 13
Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, et al.
Methods in molecular biology (2022), pp. 275-387
Closed Access | Times Cited: 13
Pharmacogenomics of drugs used to treat brain disorders
Ramón Cacabelos
Expert Review of Precision Medicine and Drug Development (2020) Vol. 5, Iss. 3, pp. 181-234
Closed Access | Times Cited: 20
Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy
Jinmiao Lu, Xiuzhe Wang, Lili Wan, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 20
Synaptic Pruning in Alzheimer’s Disease: Role of the Complement System
Frederic H Brucato, Daniel E. Benjamin
Global Journal of Medical Research (2020), pp. 1-20
Open Access | Times Cited: 18
New 2-Aryl-9-methyl-β-carbolinium salts as Potential Acetylcholinesterase Inhibitor agents: Synthesis, Bioactivity and Structure–Activity Relationship
Bohang Zhou, Bingyu Zhang, Xingqiang Li, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 17
Design, synthesis, in vitro evaluation of a new pyrrolo[1,2‐a]thiazolo[5,4‐d]pyrimidinone derivatives as cholinesterase inhibitors against Alzheimer's disease
Yan Zeng, Lifei Nie, Liu Liu, et al.
Journal of Heterocyclic Chemistry (2022) Vol. 59, Iss. 6, pp. 1086-1101
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top